Navigation Links
Agendia Appoints Peter W. Schineller as Chief Commercial Officer
Date:6/3/2013

IRVINE, Calif. and AMSTERDAM, June 3, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, today announced the addition of Peter W. Schineller as its Chief Commercial Officer.  In this newly created position, Mr. Schineller will lead Agendia's global commercialization activities as it delivers technologies to translate personalized diagnostics into actionable, patient-centered solutions for clinicians. 

Mr. Schineller's 25-year professional career spans both the diagnostic and pharmaceutical industry.  Most recently, Mr. Schineller served as Senior Vice President and Chief Commercial Officer at Alexza Pharmaceuticals. Prior to that, he was Senior Vice President and General Manager at Ventana Medical Systems, a Roche company; and Senior Vice President Sales, Marketing and Commercial Operations, at Genoptix Medical Laboratories, acquired by Novartis. 

Mr. Schineller was also a co-founder at Verus Pharmaceuticals and held positions of increasing responsibility in sales and marketing with Abbott Laboratories, Dura/Elan and Cypress Bioscience.  Prior to entering the healthcare industry, Mr. Schineller served as a Commissioned Officer in the United States Marine Corps where he attained the rank of Captain.

"As we continue our growth momentum into 2013, we are committed to building out a world class organization capable of managing and growing a much larger company.  To that end, we are thrilled to add Peter Schineller to our executive team," said David Macdonald , Agendia's Chief Executive Officer. "Mr. Schineller's depth of experienced senior leadership of global commercial organizations will help us perpetuate our volume growth, which exceeded 140 percent in 2012."

About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­®, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.  For more information, please visit www.agendia.com.Contact:Matt Clawson or 

Liz Dowling (Medical & Consumer Media)Len Hall (Financial Media)

Dowling & Dennis Public RelationsAllen & Caron Inc. 949-474-4300

415-388-2794matt@allencaron.com 

Liz@DowlingDennis.netlen@allencaron.com   


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2. Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
3. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
4. Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
5. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
6. Agendia Appoints Dr. Neil M. Barth MD, FACP, as Chief Medical Officer
7. Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
8. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
9. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
10. Nephros Appoints John C. Houghton as President and Chief Executive Officer
11. Elsevier Appoints New President of Elsevier CPM Resource Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... consumer insights on healthcare, announced today that it has ... report Cool Vendor in Life Sciences, 2016, ... 15, 2016.  The report focuses on life-science- oriented analytics, ... insight from patients and doctors, confirm medication ingestion, and ...
(Date:4/28/2016)... -- Dr. Vivek Ahuja , ... Ste phen Schmidt Join ... cloud-based software solutions for life sciences, today announced key new leaders ... of insight to a growing business.  This will bolster the company,s ... Phillips joined ArisGlobal in the position of Vice President - ...
(Date:4/28/2016)... April 28, 2016   Acsis , a leading ... leading IT market research and advisory firm IDC has ... IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 ... provides an assessment of the capabilities and business strategies ... software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... ... News on April 4th, 2016 questioned the use of the HyProCure sinus ... as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when ...
(Date:4/29/2016)... New York (PRWEB) , ... April 30, 2016 , ... ... Dobbs Ferry campus. The following programs will be expanding due to high demand: ... (HRM). The expansion will begin this summer. , School of Business ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for ... and mood optimization products to the store is just one more way Shamangelic ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy ... May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
Breaking Medicine News(10 mins):